Arecor Therapeutics (LON:AREC) Posts Earnings Results

Arecor Therapeutics (LON:AREC) issued its quarterly earnings data on Thursday. The company reported GBX (8) EPS for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a net margin of 38.74% and a return on equity of 14.26%.

Arecor Therapeutics Trading Down 2.1%

Shares of Arecor Therapeutics stock traded down GBX 1.50 during trading on Thursday, hitting GBX 71. 73,229 shares of the company were exchanged, compared to its average volume of 24,898. The firm’s fifty day moving average price is GBX 71.73 and its 200 day moving average price is GBX 67.95. Arecor Therapeutics has a 1-year low of GBX 56 and a 1-year high of GBX 95. The firm has a market capitalization of £26.81 million, a P/E ratio of 35.50 and a beta of -0.18. The company has a debt-to-equity ratio of 1.52, a current ratio of 4.35 and a quick ratio of 6.24.

About Arecor Therapeutics

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.